At a glance
ClinicalIndex Comparison Record- ✓Age older than 6 months
- ✓B-cell malignancy with CD19/CD20/CD22/CD30/CD38/CD70/CD123 surface expression
- ✓Expected survival greater than 1 month
- ✕Active uncontrolled bacterial, fungal, or viral infection
- ✕HIV infection
- ✕Active HBV and HCV infection
- ✕Pregnant or nursing mothers
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
In Brief
A Phase 1 clinical trial evaluating 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, and 4 other interventions for B-cell Malignancies. Currently recruiting, targeting 100 participants across 1 site.
Detailed Summary
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Study Details
Timeline
Arms & Interventions
Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
Interventions
4SCAR19 and 4SCAR22
4SCAR19 and 4SCAR38
4SCAR19 and 4SCAR20
4SCAR19 and 4SCAR123
4SCAR19 and 4SCAR70
4SCAR19 and 4SCAR30